The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Kristinsson, S. Y., Landgren, O., Dickman, P. W., Derolf, Å. R., & Björkholm, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0100 · Cited by 319
Dimopoulos, M. A., Barlogie, B., Smith, T. L., & Alexanian, R. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-12-931 · Cited by 208
Bladé, J., Kyle, R. A., & Greipp, P. R. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.5191061.x · Cited by 201
Bladé, J., Lust, J. A., & Kyle, R. A. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2398 · Cited by 198
High Serum Levels of Lactic Dehydrogenase Identify a High-Grade Lymphoma-like Myeloma
Barlogie, B., Smallwood, L., Smith, T., & Alexanian, R. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-7-521 · Cited by 142
Extramedullary multiple myeloma escapes the effect of thalidomide.
Rosiñol, L., Cibeira, M. T., Bladé, J., Esteve, J., Aymerich, M., Rozman, M., Segarra, M., Cid, M. C., Filella, X., & Montserrat, E. (2004) · PubMed · Cited by 134
Bortezomib: an effective agent in extramedullary disease in multiple myeloma
Rosiñol, L., Cibeira, M. T., Uriburu, C., Yantorno, S., Salamero, O., Bladé, J., & Montserrat, E. (2006) · European Journal Of Haematology · doi:10.1111/j.0902-4441.2005.t01-1-ejh2462.x · Cited by 131
Damaj, G. L., Mohty, M., Vey, N., D’Incan, E., Bouabdallah, R., Faucher, C., Stoppa, A., & Gastaut, J. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00331.x · Cited by 129
Thalidomide in multiple myeloma: lack of response of soft‐tissue plasmacytomas
Bladé, J., Perales, M., Rosiñol, L., Tuset, M., Montoto, S., Esteve, J., Cobo, F., Villela, L., Rafel, M., Nomdedeu, B., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02765.x · Cited by 101
Huang, S., Yao, M., Tang, J., Lee, W., Tsay, W., Cheng, A., Wang, C., Chen, Y., Shen, M., & Tien, H. (2007) · Cancer · doi:10.1002/cncr.22850 · Cited by 100
Pérez‐Simón, J. A., Sureda, A. M., Fernández‐Avilés, F., Sampol, A., Cabrera, J. R., Caballero, D. M., Martino, R., Petit, J., Tomás, J. F., Moraleda, J. M., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404085 · Cited by 95
Alegre, A. M., Granda, A., Martínez Chamorro, C., Díaz Mediavilla, J., Martínez, R., García Laraña, J., Lahuerta, J. J., Sureda, A. M., Bladé, J., de la Rubia, J., et al. (2002) · PubMed · doi:10.5281/zenodo.11276358 · Cited by 89
Dawson, M. A., Patil, S., & Spencer, A. G. (2007) · Haematologica · doi:10.3324/haematol.10297 · Cited by 89
Zeiser, R., Deschler-Baier, B., Bertz, H., Finke, J., & Engelhardt, M. M. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704713 · Cited by 81
Terpos, E., Rezvani, K., Basu, S., Milne, A., Rose, P. E., Scott, G. L., Rahemtulla, A., Samson, D., & Apperley, J. F. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00531.x · Cited by 69
Patriarca, F. F., Prosdocimo, S., Tomadini, V., Vasciaveo, A., Bruno, B., & Fanin, R. (2005) · PubMed · Cited by 65
Avigdor, A., Raanani, P., Levi, I., Hardan, I., & Ben‐Bassat, I. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109099330 · Cited by 60
Lack of response to thalidomide in plasmacytomas
Myers, B., Grimley, C., Crouch, D. J. M., & Dolan, G. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.0115_1cr-6.x · Cited by 27
Cited by
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R. A., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.019 · Cited by 500
Usmani, S. Z., Heuck, C., Mitchell, A., Szymonifka, J., Nair, B., Hoering, A., Alsayed, Y., Waheed, S., Haider, S., Restrepo, A., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.065698 · Cited by 394
Dimopoulos, M. A., Hillengass, J., Usmani, S., Zamagni, E., Lentzsch, S., Davies, F. E., Raje, N., Sezer, O., Zweegman, S., Shah, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9961 · Cited by 393
Metadata
- Authors
- Varettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C., & Lazzarino, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 21
- Issue
- 2
- Pages
- 325-330
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2095642828
- Cited by
- 487
- References
- 30
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.